These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23014900)

  • 41. Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Nieman K; Serruys PW; Onuma Y; van Geuns RJ; Garcia-Garcia HM; de Bruyne B; Thuesen L; Smits PC; Koolen JJ; McClean D; Chevalier B; Meredith I; Ormiston J
    J Am Coll Cardiol; 2013 Nov; 62(19):1813-4. PubMed ID: 23933536
    [No Abstract]   [Full Text] [Related]  

  • 42. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial.
    Onuma Y; Serruys PW; Perkins LE; Okamura T; Gonzalo N; García-García HM; Regar E; Kamberi M; Powers JC; Rapoza R; van Beusekom H; van der Giessen W; Virmani R
    Circulation; 2010 Nov; 122(22):2288-300. PubMed ID: 20975003
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bioabsorbable drug-eluting stents: the future of coronary angioplasty?
    Macaya C; Moreno R
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):598-9. PubMed ID: 18679382
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Why do we need post-dilation after implantation of a bioresorbable vascular scaffold even for a soft lesion?
    Naganuma T; Latib A; Panoulas VF; Sato K; Miyazaki T; Colombo A
    JACC Cardiovasc Interv; 2014 Sep; 7(9):1070-2. PubMed ID: 25234682
    [No Abstract]   [Full Text] [Related]  

  • 45. Bioabsorbable scaffold optimization in provisional stenting: insight from optical coherence tomography.
    Foin N; Ghione M; Mattesini A; Davies JE; Di Mario C
    Eur Heart J Cardiovasc Imaging; 2013 Dec; 14(12):1149. PubMed ID: 23884966
    [No Abstract]   [Full Text] [Related]  

  • 46. Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.
    Ormiston JA; Abizaid A; Spertus J; Fajadet J; Mauri L; Schofer J; Verheye S; Dens J; Thuesen L; Dubois C; Hoffmann R; Wijns W; Fitzgerald PJ; Popma JJ; Macours N; Cebrian A; Stoll HP; Rogers C; Spaulding C;
    Circ Cardiovasc Interv; 2010 Dec; 3(6):556-64. PubMed ID: 21062998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study.
    Gomez-Lara J; Diletti R; Brugaletta S; Onuma Y; Farooq V; Thuesen L; McClean D; Koolen J; Ormiston JA; Windecker S; Whitbourn R; Dudek D; Dorange C; Veldhof S; Rapoza R; Regar E; Garcia-Garcia HM; Serruys PW
    EuroIntervention; 2012 Jun; 8(2):214-24. PubMed ID: 22030265
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
    Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
    J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current status of the Xience V® everolimus-eluting coronary stent system.
    Claessen BE; Caixeta A; Henriques JP; Piek JJ
    Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1363-74. PubMed ID: 20936921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?
    Serruys PW; Garcia-Garcia HM; Onuma Y
    Eur Heart J; 2012 Jan; 33(1):16-25b. PubMed ID: 22041548
    [No Abstract]   [Full Text] [Related]  

  • 51. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.
    Meredith IT; Verheye S; Dubois CL; Dens J; Fajadet J; Carrié D; Walsh S; Oldroyd KG; Varenne O; El-Jack S; Moreno R; Joshi AA; Allocco DJ; Dawkins KD
    J Am Coll Cardiol; 2012 Apr; 59(15):1362-70. PubMed ID: 22341736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Guide-catheter extension system facilitated multiple bioresorbable vascular scaffolds (ABSORB®) delivery in a very long and resistant coronary artery lesion.
    Ielasi A; Anzuini A
    Cardiovasc Revasc Med; 2014 Mar; 15(2):117-20. PubMed ID: 24054502
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of everolimus-eluting stents versus sirolimus-eluting stents in women.
    Badr S; Barbash IM; Dvir D; Torguson R; Xue Z; Kitabata H; Sardi G; Loh JP; Pichard AD; Waksman R
    Am J Cardiol; 2013 Jan; 111(1):21-5. PubMed ID: 23040594
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE
    EuroIntervention; 2012 May; 8(1):117-9. PubMed ID: 22580255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assimilating the current clinical data of fully bioabsorbable stents.
    Di Mario C; Borgia F
    EuroIntervention; 2009 Dec; 5 Suppl F():F103-8. PubMed ID: 22100669
    [No Abstract]   [Full Text] [Related]  

  • 57. Bioresorbable vascular scaffold in patients with complex coronary artery disease.
    Tamburino CI; Capranzano P; Longo G; Immè S; Tamburino G; Scalia M; Condorelli A; Francaviglia B; LA Manna A; Sgroi C; Grasso C; DI Salvo ME; Capodanno D; Tamburino C
    Minerva Cardioangiol; 2016 Aug; 64(4):481-6. PubMed ID: 27128353
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vascular restoration therapy: the fourth revolution in interventional cardiology and the ultimate "rosy" prophecy.
    Wykrzykowska JJ; Onuma Y; Serruys PW
    EuroIntervention; 2009 Dec; 5 Suppl F():F7-8. PubMed ID: 22100680
    [No Abstract]   [Full Text] [Related]  

  • 59. Optical coherence tomography follow-up after bioresorbable in metallic and metallic in bioresorbable stenting: tackling in-stent restenosis in the era of bioresorbable vascular scaffolds.
    Frangieh AH; Templin C; Binder RK
    Eur Heart J; 2015 Aug; 36(32):2183. PubMed ID: 26040803
    [No Abstract]   [Full Text] [Related]  

  • 60. Complex coronary artery bifurcation treatment utilizing everolimus-eluting bioresorbable vascular scaffolds and optical coherence tomography.
    Chan W; Shah A; Džavík V; Overgaard CB
    Coron Artery Dis; 2014 Nov; 25(7):629-31. PubMed ID: 25248139
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.